Pfizer's revenue outlook remains a subject of interest among investors and analysts.
Recent losses in Pfizer's stocks have triggered a concerted recalibration among investors. Despite the company's
unexpected setback, there are speculations of Pfizer stocks
bouncing back in the near future. Furthermore, Pfizer's upcoming
weight loss approach is suggested to drive its stock value upwards. The pharmaceutical giant's advances in its
weight loss pill study have also injected optimism in the market. On the other hand, a miss by Pfizer's Covid/Flu shot stalled the company's stock momentarily. Regarding dividends, Pfizer is considered a
passive income source and has returned $5 billion to its shareholders in Q2 2024. There's potential for a stock rebound to the 2021 highs of
$60 with a
satisfactory Q2. However, a
30% fall in the last year has cast doubt among some investors. There is also a call to add Pfizer to investment portfolios due to its undervalued status, and
billionaire investors are reportedly buying the beaten-down stock.
Pfizer Stocks News Analytics from Wed, 13 Dec 2023 08:00:00 GMT to Sun, 22 Sep 2024 04:50:43 GMT -
Rating 1
- Innovation 0
- Information 2
- Rumor -4
